Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Mar;81(3):335-343.
doi: 10.1136/annrheumdis-2021-221276. Epub 2021 Oct 27.

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database

Peter C Taylor  1 , Tsutomu Takeuchi  2 , Gerd R Burmester  3 , Patrick Durez  4 , Josef S Smolen  5 , Walter Deberdt  6 , Maher Issa  6 , Jorge Ross Terres  6 , Natalia Bello  6 , Kevin L Winthrop  7
Affiliations
Meta-Analysis

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database

Peter C Taylor et al. Ann Rheum Dis. 2022 Mar.

Abstract

Objective: To report long-term safety from the completed extension trial of baricitinib, an oral selective Janus kinase inhibitor, in patients with active rheumatoid arthritis (RA).

Methods: Treatment-emergent adverse events are summarised from an integrated database (9 phase III/II/Ib and 1 long-term extension) of patients who received any baricitinib dose (All-bari-RA). Standardised incidence ratio (SIR) for malignancy (excluding non-melanoma skin cancer (NMSC)) and standardised mortality ratio (SMR) were estimated. Additional analysis was done in a subset of patients who had ever taken 2 mg or 4 mg baricitinib.

Results: 3770 patients received baricitinib (14 744 patient-years of exposure (PYE)). All-bari-RA incidence rates (IRs) per 100 patient-years at risk were 2.6, 3.0 and 0.5 for serious infections, herpes zoster and major adverse cardiovascular events (MACE), respectively. In patients aged ≥50 with ≥1 cardiovascular risk factor, the IR for MACE was 0.77 (95% CI 0.56 to 1.04). The IR for malignancy (excluding NMSC) during the first 48 weeks was 0.6 and remained stable thereafter (IR 1.0). The SIR for malignancies excluding NMSC was 1.07 (95% CI 0.90 to 1.26) and the SMR was 0.74 (95% CI 0.59 to 0.92). All-bari-RA IRs for deep vein thrombosis (DVT)/pulmonary embolism (PE), DVT and PE were 0.5 (95% CI 0.38 to 0.61), 0.4 (95% CI 0.26 to 0.45) and 0.3 (95% CI 0.18 to 0.35), respectively. No clear dose differences were noted for exposure-adjusted IRs (per 100 PYE) for deaths, serious infections, DVT/PE and MACE.

Conclusions: In this integrated analysis including long-term data of baricitinib from 3770 patients (median 4.6 years, up to 9.3 years) with active RA, baricitinib maintained a similar safety profile to earlier analyses. No new safety signals were identified.

Trial registration number: NCT01185353, NCT00902486, NCT01469013, NCT01710358, NCT02265705, NCT01721044, NCT01721057, NCT01711359 and NCT01885078.

Keywords: autoimmune diseases; biological therapy; rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: PCT has received consultant fees from AbbVie, Biogen, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, BMS, Pfizer, Roche, Celltrion, Sanofi, Nordic Pharma, Fresenius and UCB; and grant/research support from Celgene, Galapagos, Janssen and Lilly. TT has received grant/research support from Daiichi Sankyo, Takeda, Nippon Kayaku, JCR Pharma, Astellas, Chugai, AbbVie GK, Asahi Kasei Pharma, Mitsubishi Tanabe, UCB Japan and Eisai; consulting fees from Astellas, AbbVie GK, Gilead, Daiichi Sankyo, Taisho Pharma, Nippon Kayaku, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Novartis, Mitsubishi Tanabe and Chugai; and speakers’ bureau fees from Mitsubishi Tanabe, Pfizer, Astellas, Daiichi Sankyo, Eisai, Sanofi, Novartis, Eli Lilly, Gilead, AbbVie GK, Bristol-Myers Squibb and Chugai. G-RRB has received honoraria for lectures and consulting from AbbVie, Gilead, Lilly and Pfizer. PD has received fees for speakers' bureau from BMS, Sanofi, Eli Lilly and Celltrion. JSS has received grant/research support from AbbVie, Eli Lilly and Company, Janssen, MSD, Novartis, Pfizer and Roche; and consultancy fees from AbbVie, Amgen, AstraZeneca, Astro, BMS, Celgene, Celltrion, Chugai, Eli Lilly and Company, Gilead, ILTOO, Janssen, MedImmune, MSD, Novartis, Pfizer, Roche, Samsung, Sanofi and UCB. WD, MI, JRT and NB are employees and stockholders of Eli Lilly and Company. KLW has received grant/research support from Pfizer and BMS; and consulting fees from Pfizer, UCB, AbbVie, Eli Lilly and Company, Amgen, BMS, Galapagos and Gilead.

Figures

Figure 1
Figure 1
Serious infections and herpes zoster over time for the All-bari-RA analysis set. Cumulative incidence rate of serious infections (A) and herpes zoster (B) by time period for the All-bari-RA analysis set. Data are presented by IR per 100 PY at risk. The number of total patients and patients with events, as well as the total PY per time period, are also provided. bari, baricitinib; IR, incidence rate; PY, patient-years; RA, rheumatoid arthritis.
Figure 2
Figure 2
Malignancy-related events over time for the All-bari-RA analysis set. Cumulative incidence rate of (A) malignancy (excluding NMSC) and (B) NMSC by time period for the All-bari-RA analysis set. Data are presented by IR per 100 PY at risk. The number of total patients and patients with events, as well as the total PY per time period, are also provided in both panels. bari, baricitinib; IR, incidence rate; NMSC, non-melanoma skin cancer; PY, patient-years; RA, rheumatoid arthritis.
Figure 3
Figure 3
MACE over time for the All-bari-RA analysis set. Cumulative incidence rate of MACE (calculated for the five phase III studies and the LTE) by time period for the All-bari-RA analysis set. Data are presented by IR per 100 PY at risk. The number of total patients and patients with events, as well as the total PY per time period, are also provided. bari, baricitinib; IR, incidence rate; LTE, long-term extension; MACE, major adverse cardiovascular event; PY, patient-years; RA, rheumatoid arthritis.
Figure 4
Figure 4
Thromboembolic events over time for the All-bari-RA analysis set. Cumulative incidence rate of (A) DVT/PE, (B) PE and (C) DVT by time period for the All-bari-RA analysis set. Data are presented by IR per 100 PY at risk. The number of total patients and patients with events, as well as the total PY per time period, are also provided in both panels. bari, baricitinib; DVT, deep vein thrombosis; IR, incidence rate; PE, pulmonary embolism; PY, patient-years; RA, rheumatoid arthritis.
See this image and copyright information in PMC

References

    1. Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 2010;184:5298–307. 10.4049/jimmunol.0902819 - DOI - PubMed
    1. Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 2017;376:652–62. 10.1056/NEJMoa1608345 - DOI - PubMed
    1. Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 2016;374:1243–52. 10.1056/NEJMoa1507247 - DOI - PubMed
    1. Dougados M, van der Heijde D, Chen Y-C, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 2017;76:88–95. 10.1136/annrheumdis-2016-210094 - DOI - PMC - PubMed
    1. Fleischmann R, Schiff M, van der Heijde D, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 2017;69:506–17. 10.1002/art.39953 - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data